CJC-1295 and ipamorelin attract interest because they can stimulate growth-hormone signaling. That does not show that either builds muscle, reduces body fat, improves sleep or speeds everyday recovery. The human studies reviewed here asked different questions: CJC-1295 studies measured hormones and blood markers; a published ipamorelin trial tested recovery after bowel surgery and did not establish its primary benefit.
This is a comparison of what those studies can support, not a head-to-head treatment ranking. The selected studies tested the substances separately. They do not test a CJC-1295/ipamorelin mixture.
Claim check 1 · a hormone result becomes a muscle or recovery promise
Does a rise in growth hormone show a useful benefit?
Identify the question the study actually asked
CJC-1295 is a modified growth-hormone-releasing hormone analogue. Researchers studied a long-acting preparation that attaches to albumin, a blood protein, through a modification called DAC. The original 2006 report describes two randomized, placebo-controlled, double-blind studies in healthy adults aged 21–61, lasting 28 and 49 days. Their main measurements were growth hormone (GH), insulin-like growth factor 1 (IGF-1) and how the compound behaved in the body. They were not trials of muscle strength, injury healing, sleep improvement or treatment of diagnosed growth hormone deficiency. Teichman and colleagues, 2006, original indexed abstract.
Keep the measured result attached to that question
The report found increases in mean GH concentrations of 2–10 times baseline for at least six days, and IGF-1 increases of 1.5–3 times baseline for 9–11 days after a single study exposure. These are blood-hormone findings, not percentages of muscle gained or fat lost. A sustained signal can establish biological activity without establishing whether people feel, function or recover better. The abstract also reports no serious adverse reactions in these small, short studies; that is not a long-term safety guarantee. Original results and study scope.
Check whether another paper adds new patients or a new kind of answer
A later full 2009 paper examined serum proteins in eleven healthy men selected from an earlier CJC-1295 study cohort, before and one week after exposure. It identified changes in protein spots and explored their relationship with GH or IGF-1. This is a distinct protein analysis, not eleven new patients in an independent trial of muscle or recovery. Its authors described potential biomarkers whose biological meaning still needed clarification. More publications do not automatically mean more independent benefit trials. Sackmann-Sala and colleagues, 2009, Methods §2.1 and Results; earlier GH-pulsatility report.
Stop where the evidence stops
A muscle, fat-loss or recovery claim needs measurements of that outcome in the relevant people. The hormone and protein results above do not supply those measurements. They also do not validate a product labeled “CJC-1295 without DAC”: FDA's 2024 review distinguishes DAC-modified and other CJC-related substances and notes uncertainty about the exact salt used in the published research. A shared name is not enough to transfer the result. FDA CJC-1295 assessment, printed pp. 3–7 and 32–33.
Claim check 2 · a specific clinical recovery test becomes a general recovery promise
What happened when ipamorelin was tested after surgery?
Separate hormone research from a patient-outcome trial
Ipamorelin acts at the ghrelin receptor, a signaling system connected with GH release and digestive movement. An original 1999 study in healthy male volunteers measured ipamorelin and GH concentrations after intravenous exposure and modeled their relationship. It characterized a hormone response; it did not measure body composition, strength or everyday recovery. Gobburu and colleagues, 1999, original indexed abstract.
The later published clinical trial asked a different question: could intravenous ipamorelin help hospitalized adults recover gastrointestinal function after small- or large-bowel resection? This is postoperative ileus research, not a study of healthy people using a wellness product. Beck and colleagues, 2014, original indexed abstract; earlier trial registry.
Read the primary comparison before the favorable-looking number
The study enrolled 117 people; 114 received study treatment and were included in the modified intention-to-treat analysis: 56 ipamorelin and 58 placebo. The published primary endpoint was time from the first study dose to tolerating a standardized solid meal. It is not time from surgery, and it is not a general measure of healing.
Median time to a tolerated meal: 25.3 hours with ipamorelin versus 32.6 hours with placebo; P = .15.
The numerical gap was not statistically significant. It did not establish a reliable primary recovery advantage. Secondary efficacy comparisons also did not show statistically significant differences. A favorable finding in the open-surgery subgroup does not replace the negative overall primary comparison. It is also wrong to turn this result into proof that every possible use is ineffective. The outcome belongs to the tested population, preparation and clinical question. Original abstract; FDA clinical assessment, printed pp. 22–24.
Keep a later completed trial separate from published results
A distinct later phase 2 record, NCT01280344, lists 320 actual participants and a completed gastrointestinal-recovery study, with completion in 2014. At the November 16, 2026 check, the registry had no posted results. That is an evidence gap. The record does not tell us the treatment worked, failed or was safe, and its 320 participants must not be added to the earlier published trial's denominator. “Completed” describes study status, not a positive result.
Stop before changing the route, people or promised outcome
Hospital intravenous findings do not establish the effects or safety of a product used under the skin, alone or in a mixture. Neither the early hormone model nor the published postoperative comparison supplies a muscle-gain, fat-loss, sleep or everyday-recovery result for such products. The appropriate answer to that transfer is “not established by these sources,” not a recommended alternative regimen. FDA assessment, clinical-efficacy and safety sections.
How to check a CJC-1295/ipamorelin combination claim
Suppose a claim says, “One compound raises growth hormone, and the other works through another receptor, so together they improve recovery.” The missing step is a human study of the actual combination and claimed outcome. Mechanisms and separate studies do not supply that result.
- Identify what was studied. Does the cited document name a combined preparation, or only one component? Is the CJC form DAC-modified, non-DAC or unclear?
- Name the outcome. Was it a blood-hormone level, a protein pattern, postoperative meal tolerance, or the muscle/sleep/recovery benefit being advertised?
- Recover the missing information. If the formulation, population or outcome does not match, keep the claim unresolved. Return to the original document or request the actual clinical evidence; do not fill the gap with another compound's result.
The sources on this page do not test the two substances head to head or together. This selected-source comparison therefore cannot name a winner, prove a mixture's benefit or establish that combining them reduces risk. For the existing identity records and retained additional documents, see the CJC-1295 profile and ipamorelin profile.
What risks matter when reading the benefit claims?
CJC-1295: FDA's review of the small healthy-adult studies describes injection-site reactions, headache, flushing and transient low blood pressure, among other reported effects. Small, short observations cannot settle uncommon or long-term harms. The uncertain chemical forms further limit transfer to a product with a similar name. FDA assessment, printed pp. 36–38.
FDA also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction (widening of blood vessels throughout the body). Its safety statement says available clinical data are limited. The absence of a serious reaction in a small trial does not erase those reported concerns. FDA safety statement, CJC-1295 entry, checked November 16, 2026.
Ipamorelin: in the surgical study summarized by FDA, low potassium was reported in 12.5% of the ipamorelin group versus 3.4% of placebo; high blood glucose at discharge in 14.3% versus 8.6%. Serious adverse events occurred in 10 of 56 versus 9 of 58 participants. Two ipamorelin-treated participants had fatal serious events after major postoperative complications. Whether those deaths were related to ipamorelin was unclear. Surgery, cancer and underlying illness complicate causation; neither “the drug caused the deaths” nor “it was proven safe” follows from this comparison. These hospital findings also do not establish a safety profile for a different route or a combined product. FDA assessment, printed pp. 32–34.
Source scope, formulation and policy limits
This article checks selected original indexed abstracts, the full 2009 protein-analysis paper, relevant clinical sections of FDA's 2024 scientific assessments and the two trial-registry records. Full versions of the 2006 CJC trial report and the 2014 ipamorelin article were unavailable to this review; the postoperative numbers were cross-checked between the original abstract and FDA's discussion. This is not a complete literature review or clinician review.
The CJC human reports appear to involve a long-acting DAC preparation, with uncertainty about salt identity. Ipamorelin free base and acetate are distinct substance forms, and FDA describes the published surgical preparation as unspecified. These limits matter when matching a claim to a study. The FDA documents are historical bulk-substance assessments, not product approvals or a current blanket determination about compounding. This article does not establish whether a particular product or practice is currently permitted. It provides no treatment, dosing, administration or purchase protocol.
Sources10 linked sources
- Teichman et al. (2006), prolonged GH/IGF-1 stimulation by CJC-1295 in healthy adults. Original indexed abstract; full paper unavailable.
- Ionescu and Frohman (2006), GH pulsatility during CJC-1295 stimulation. Original indexed abstract; DOI 10.1210/jc.2006-1702.
- Sackmann-Sala et al. (2009), serum-protein profile changes. Full manuscript, especially Methods §2.1 and Results; eleven-person subset of earlier cohort.
- Gobburu et al. (1999), ipamorelin pharmacokinetic/pharmacodynamic modeling in healthy volunteers. Original indexed abstract.
- Beck et al. (2014), randomized postoperative ipamorelin study. Original indexed abstract; full article unavailable.
- NCT00672074: earlier postoperative gastrointestinal-recovery study; actual enrollment 117. Registry and publication describe outcomes at different levels of detail.
- NCT01280344: distinct later completed phase 2 study, actual enrollment 320, no posted results at this check.
- FDA safety-risk statement, CJC-1295 and ipamorelin entries, checked November 16, 2026. Safety concerns are distinct from a current blanket legal determination.
- FDA December 2024 CJC-1295-related bulk-substance assessment, selected clinical-evidence and safety sections.
- FDA October 2024 ipamorelin-related bulk-substance assessment, selected clinical-efficacy and safety sections.